Jeff Lamothe was named President and Chief Executive Officer of Aptevo Therapeutics Inc., succeeding Marvin L. White. As of November 14, 2026, Aptevo Therapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 3, 2026, naming 2 appointments and 1 departure (Form 8-K, February 3, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Aptevo Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Marvin L. White · Role: President and Chief Executive Officer · Effective: 2026-04-01 · 8-K, 2026-02-03
- · In / out: In · Person: Jeff Lamothe · Role: Director · 8-K, 2026-02-03
- · In / out: In · Person: Jeff Lamothe · Role: President and Chief Executive Officer · 8-K, 2026-02-03
Aptevo Therapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-03. It names 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Aptevo Therapeutics Inc. files it.
Also on the record for Aptevo Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 12, 2026 | Stake report, Schedule 13G/A, by Ayrton Capital LLC | 3.72% of the class | 5%+ stakes | Source |
| August 26, 2026 | Form D, private offering | $3.47M sold | Form D page | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 6.3% of the class | 5%+ stakes | Source |
| June 22, 2026 | Stake report, Schedule 13G, by NIOWAVE, INC. | 12.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 8.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | — | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by BANK OF AMERICA CORP /DE/ | — | 5%+ stakes | Source |
| October 6, 2025 | Stake report, Schedule 13G, by BANK OF AMERICA CORP /DE/ | 15% of the class | 5%+ stakes | Source |
| September 17, 2025 | Stake report, Schedule 13G, by Point72 Asset Management, L.P. | 9.1% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by L1 Capital Global Opportunities Master Fund, Ltd. | 4.99% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G, by Ayrton Capital LLC | 10% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Aptevo Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Aptevo Therapeutics Inc. and the records around it.
Aptevo Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Company profile and every filing Aug 2026
- Form D filing Aug 2026
- Who owns it
Companies that share a holder
- YA II PN, Ltd. also filed stake reports on 14 other companies: Ives Ultra AI Opportunities Inc. (Oct 2026), Beneficient (Oct 2026), Optimi Health Corp. (Oct 2026)
- Ayrton Capital LLC also filed stake reports on 35 other companies: AVAX ONE TECHNOLOGY LTD. (Nov 2026), Azitra, Inc. (Nov 2026), BTC Digital Ltd. (Nov 2026)
- L1 Capital Global Opportunities Master Fund, Ltd. also filed stake reports on 42 other companies: Youlife Group Inc. (Nov 2026), INLIF Ltd (Oct 2026), DarkIris Inc. (Oct 2026)
Watch Aptevo Therapeutics Inc.
Get an email when Aptevo Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aptevo Therapeutics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Aptevo Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aptevo Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-03 | Out | President and Chief Executive Officer | 2026-04-01 | 8-K, 2026-02-03 | |
| 2026-02-03 | In | Director | 8-K, 2026-02-03 | ||
| 2026-02-03 | In | President and Chief Executive Officer | 8-K, 2026-02-03 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Marvin L. White, President and Chief Executive Officer (filed 2026-02-03):
Mr. White's intention to resign was not because of any disagreement with management or the Board of Directors of the Company (the "Board") on any matter relating to the Company's operations, policies or practices.
Who leads Aptevo Therapeutics Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President and Chief Executive Officer: Marvin L. White, departure reported, effective 2026-04-01 (filed 2026-02-03). No successor is named in these filings.
- Director: Jeff Lamothe, appointed (filed 2026-02-03).
New leaders reset buying decisions — get the Full Report on Aptevo Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Aptevo Therapeutics Inc. (free up to 3)
Find people with the same kind of experience as the President and Chief Executive Officer at Aptevo Therapeutics Inc., with the record behind each one.
Find candidates like President and Chief Executive Officer at Aptevo Therapeutics Inc.Every change, in the filing's words
Departing: Marvin L. White, President and Chief Executive Officer, effective 2026-04-01
On January 30, 2026, Marvin L. White notified Aptevo Therapeutics Inc. (the "Company") of his intent to retire as the Company's President and Chief Executive Officer, effective as of April 1, 2026 (the "Transition Date").
Appointed: Jeff Lamothe, Director
In addition, the Board has appointed Mr. Lamothe to serve as a Class III director of the Company to hold office until the 2028 annual meeting of stockholders of the Company and a member of the Executive Committee of the Board effective as of the Transition Date.
Appointed: Jeff Lamothe, President and Chief Executive Officer
In his capacity as President and Chief Executive Officer, Mr. Lamothe will serve as the Company's principal executive officer.
- On February 3, 2026, the Company announced that effective as of the Transition Date, Mr. White will transition to the role of Executive Chair of the Board, and Jeff Lamothe, the Company's current Chief Operating Officer, will assume the role of President and Chief Executive Officer of the Company.
- Accordingly, the size of the Board will be increased from six directors to seven directors effective as of the Transition Date.
- As Executive Chair, Mr. White will work closely with Mr. Lamothe and the executive team to provide mentorship and continuity and support the Company's long-term growth.
- John E. Niederhuber, M.D., currently serving on the Board and as Chairman of the Board, will serve as Lead Independent Director effective as of the Transition Date.
- Mr. Lamothe, age 60, has served as the Company's Executive Vice President and Chief Operating Officer since March 2023, previously Executive Vice President and Chief Financial Officer since February 2022 and Senior Vice President and Chief Financial Officer since July 2016.
- Mr. Lamothe previously served as Emergent's Vice President Finance, Biosciences Division.
- Mr. Lamothe assumed this role in February 2014 when Emergent concluded the acquisition of Cangene Corporation ("Cangene"), where he was Chief Financial Officer.
- Mr. Lamothe assumed the role of Chief Financial Officer of Cangene in August 2012.
Aptevo Therapeutics Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Aptevo Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
